Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
These stocks can help you withstand (almost) any storm.
High-yield ETFs built purely on yield rankings carry a hidden flaw that only shows up when it's too late, and one fund uses a decade-long dividend track record as a filter before yield ever enters the picture.
Johnson & Johnson has surged more than 50% in a year and now sits within striking distance of its 52-week high, but a closer look at the valuation, insider activity, and pipeline pressures raises a pointed question about who actually wins from here.
Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.
Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.
J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.
Intuitive Surgical is down more than 30% this year, and one investor keeps buying anyway, convinced that a once-per-decade hardware cycle and an $8.6 billion cash fortress make the drawdown a gift rather than a warning.
For years, healthcare and semiconductor stocks weren’t particularly tied to each other. In other words, they increasingly go in opposite directions: when chips sell off, healthcare has tended to catch a bid. After years of underperformance, healthcare investors are enjoying a burst of momentum amid the recent nervousness around AI.
Pulling $54,000 a year from a $950,000 rollover IRA sounds like a math problem, but the real trap is hidden in the yield tier you choose and what it quietly does to your principal over time.
In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these...
Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts’ average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on […]
Turning 65 comes with a quiet IRS bonus most retirees overlook, and the way you deploy it in the next few months could determine whether your retirement generates real monthly cash or simply keeps pace with inflation.
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet […]
Most 140-year-old companies are coasting. Johnson & Johnson (JNJ) is restructuring. And that's the part of the J&J story that rarely gets enough attention. When people think of this company, they think of dividend checks and baby powder. A steady, predictable blue-chip that you hold ...
Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.
During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]
Four stocks built on investment-grade balance sheets and decades of payout discipline could quietly generate thousands in annual passive income without requiring you to touch a thing after you buy them.
ISRG's premium valuation faces scrutiny as strong Q2 growth, higher margins and expanding robotic platforms support its 2026 outlook.
Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J’s MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon […]
Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.
The pharmaceutical icon's dividend yield has been pared back by the stock's recent rally, driven by a new growth initiative.
Retiring on dividends at 60 sounds straightforward until you realize the yield tier you choose today could mean the difference between an income stream that doubles over a decade and one that quietly erodes your nest egg.
A $425,000 nest egg can generate wildly different monthly paychecks depending on where you put it, but chasing the biggest number often destroys the very asset you need to last through your 70s.
Replicating a Social Security check with dividends sounds straightforward until you realize the yield you chase determines whether your income grows, stalls, or quietly disappears over the next two decades.
Intuitive Surgical is a leader in the surgical robotics space, with a large installed base and strong recurring revenues.
Consumer sentiment is flashing recession warnings, yet three blue-chip dividend legends are quietly building cases for returns that would shock most defensive investors heading into 2027.